Multiple Cancers: Nivolumab and Ipilimumab in Treating Patients With Rare TumorsResearch Question:
What are the good and bad effects of the combination of study drugs called ipilimumab
and nivolumab in treating rare cancers and cancers of unknown primary origin?
Basic Study Information
Purpose:Location: Cancer Center
If you participate in this study you will receive the study drugs ipilimumab and
nivolumab. You will receive both study drugs through a vein on the first day of each
cycle (or every 6 weeks), and you will receive nivolumab through a vein every 2 weeks.
You will continue to receive study drugs until your disease gets worse or you experience
bad side effects from the study drugs or your study doctor decides that you are not
benefiting from the study drugs.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02834013?term=S1609&rank=1
Study Reference #: CMLT18023
Lead Researcher (Principal Investigator)
Lead Researcher: Paul Barr
Study Contact InformationStudy Coordinator: Laura Mitchell
Phone: (585) 275-7763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search